Dupilumab 200/300 mg was associated with significant reduction in ACQ-5 scores at weeks 24 compared with placebo.

HOUSTON — Dupilumab has demonstrated consistency in effective asthma control across baseline levels of immunoglobulin E (IgE) among individuals with uncontrolled, moderate to severe asthma with high baseline eosinophils. This research was presented at the 2019 American College of Allergy, Asthma, & Immunology Annual Scientific Meeting, held November 7 to 11, 2019, in Houston, Texas.

Researchers conducted a post-hoc analysis of the phase 3 LIBERTY ASTHMA QUEST study (ClinicalTrials.gov Identifier:NCT02414854) to determine the effect of dupilumab on asthma control among individuals with elevated baseline eosinophils (≥150 cells/µL) using measurements of baseline IgE levels (categorized as <100, 100 to <500, or ≥500 IU/mL). Participants were given dupilumab 200/300 mg every 2 weeks or placebo.

The Asthma Control Questionnaire-5 (ACQ-5) was used to assess asthma control, in which scores of 0 to 6 corresponded with totally controlled to severely uncontrolled, respectively. The threshold for clinically meaningful change was ≥0.5 change in ACQ-5 score. At weeks 24 and 52, a mixed effects model with repeated measures was used to assess changes from baseline.

Dupilumab 200/300 mg was associated with significant reduction in ACQ-5 scores at weeks 24 (least squares mean difference [LSMD], -0.53 to -0.28; P <.05) and 52 (LSMD, -0.57 to -0.35; P <.05) compared with placebo, with the exception of dupilumab 300 mg at week 24 (<100 IgE level group: LSMD, -0.24; P =.11; ≥500 IU/mL IgE level group: LSMD, -0.22; P =.19) and at week 52 (≥500 IU/mL IgE level group: LSMD, 0.09; P =.57). Injection site reaction was the most common adverse event among both the dupilumab (15%/18%) and placebo (5%/10%) groups.

The study researchers concluded that, among individuals with “uncontrolled, moderate to severe asthma with elevated baseline eosinophils,” dupilumab demonstrated an “overall consistent [effect] across baseline IgE levels.

Reference

Carr W, Corren J, Rice M, et al. Dupilumab improved asthma control across baseline immunoglobulin E levels: Liberty Asthma Quest Study. Presented at: 2019 American College of Allergy, Asthma, & Immunology Annual Scientific Meeting; November 7-11, 2019; Houston, TX. Abstract P223.

Source: